AI is revolutionising Health Tech and healthcare in some pretty magnificent ways.
Transforming diagnostics, enhancing surgeries, and pioneering new frontiers in personalised medicine, AI has set the scene for new frontiers in providing faster and more efficient treatments and systems for patients around the world.
Yet, amid rapid technological advancements, identifying and shining spotlight on the true innovators is necessary. Who are these trailblazers, and what makes their contributions significant? Who is leading AI in healthcare?
Predictive Diagnostics: Early Detection for Better Outcomes
One of the standout areas where AI is making remarkable strides is predictive diagnostics.
Tempus AI, a health technology firm, is revolutionising predictive diagnostics through AI and data analytics. By integrating vast clinical and molecular data, Tempus develops AI-driven tests that enhance diagnostic precision and personalise treatment strategies.
For instance, their PurISTSM algorithm classifies advanced pancreatic cancer into molecular subtypes, guiding first-line therapy decisions.
They also recently acquired Arterys, a company specialising in AI medical imaging for critical conditions like liver and lung cancer.
Additionally, Tempus collaborates with companies like Imagene to advance AI-powered diagnostics for non-small cell lung cancer. Which aims to deliver rapid and reliable biomarker predictions directly from biopsy images. These innovations exemplify how AI is transforming diagnostics, enabling earlier interventions and improving patient outcomes.
(Tempus recently released their AI assistant, Tempus One)
Another notable trailblazer is Cleerly, a leader in advanced cardiovascular imaging that are transforming heart disease diagnostics with its AI-enabled digital care platform. By analysing non-invasive coronary CT angiography (CCTA) images, Cleerly’s software precisely identifies and quantifies atherosclerosis (plaque buildup) in the coronary arteries.
This detailed assessment enables healthcare providers to detect heart disease at its earliest stages. It facilitates personalised treatment plans that can prevent severe cardiac events.
AI’s predictive capabilities don’t just improve patient care – they optimise hospital resources, reducing costs and streamlining processes. By predicting hospital readmissions and managing chronic conditions more effectively, healthcare providers can significantly elevate the standard of patient care and operational efficiency.
Robotic Surgeries: Enhancing Precision, Reducing Risks
While the domestic and hospitality AI robots are stealing the limelight with menial household tasks and serving as bartenders, there’s massive progress being made in the health space.
AI-powered robotics are transforming surgery, increasing precision, reducing recovery times, and enabling minimally invasive procedures.
Key industry leaders like Intuitive Surgical with their flagship da Vinci Surgical System exemplify this innovation.
Established in 1995, Intuitive Surgical has pioneered robotic-assisted surgery with its da Vinci Surgical System. This system enhances a surgeon’s capabilities by translating hand movements into precise actions of miniaturised instruments inside the patient’s body.
(Da Vinci 5, Intuitive Surgical’s latest offering)
Equipped with a 3D high-definition vision system, da Vinci provides a magnified view of the surgical area, facilitating complex procedures with improved precision and control. Its applications span various specialties, including urology, gynecology, and cardiothoracic surgery, offering benefits such as reduced recovery times and minimized surgical trauma.
Another notable contributor includes Medtronic’s Hugo Robotic-Assisted Surgery System.
Designed with input from surgeons worldwide, Hugo offers a modular and portable design, allowing flexible configurations to suit different operating room spaces and patient needs.
The system integrates enhanced visualisation and instrumentation, utilising proven technologies across open, laparoscopic, and robotic-assisted procedures. Additionally, Hugo features secure and seamless video recording options through Touch Surgery™ Enterprise, enabling performance analysis and continuous improvement.
Accelerating Drug Development and Precision Medicine
AI has expanded beyond diagnostics and surgeries into drug discovery and personalised medicine.
Companies like Owkin leverage machine learning to analyse complex biomedical data, significantly accelerating the drug discovery process.
Founded in 2016 by Thomas Clozel, MD, and Gilles Wainrib, PhD, Owkin is a French-American AI biotechnology company specializing in applying machine learning to medical research.
The company uses federated learning (a decentralised AI approach) to analyse multimodal patient data while preserving privacy. This enables Owkin to identify novel drug candidates, optimize clinical trials, and develop AI-powered diagnostics.
Notable products include MSIntuit CRC, an AI diagnostic tool for colorectal cancer, and RlapsRisk BC, which predicts breast cancer relapse risks.
Owkin has established strategic partnerships with pharmaceutical giants like Sanofi and Bristol-Myers Squibb to advance oncology research and improve clinical trial design.
Additionally, Komodo Health harnesses AI to track patient journeys, providing insights that improve treatment efficacy and disease management strategies.
Established in 2014, Komodo Health is a healthcare technology company dedicated to reducing the global burden of disease through data-driven insights. At the core of its offerings is the Healthcare Map, a comprehensive platform that compiles de-identified data from over 330 million patient encounters across the U.S.
This resource enables life sciences companies, healthcare providers, and payers to gain real-time insights into patient journeys, treatment patterns, and health outcomes.
Komodo’s suite of software applications leverages this data to enhance clinical development, inform medical affairs strategies, and improve patient care. The company has secured significant funding, reflecting its growing influence in the healthcare analytics sector.
Organisational Adoption and Leadership
Successful AI integration into healthcare isn’t merely about technology—it’s deeply connected to organizational culture and leadership.
According to McKinsey’s recent report (March 2025), organizations achieve significantly greater success with AI when there is direct CEO oversight. McKinsey found that 28% of respondents reported their CEO directly oversees AI governance, correlating strongly with higher AI-driven business impacts.
Furthermore, businesses seeing genuine benefits from AI have fundamentally redesigned their workflows—an approach cited by 21% of respondents as critical for capturing AI’s value.
As Alexander Sukharevsky from McKinsey underscores, “Getting real value out of AI requires transformation, not just new technology.”
Future Outlook: Embracing Transformation
With 92% of companies planning increased investments in AI over the next three years, healthcare businesses must be strategic about their AI adoption approaches
Currently, only 1% of businesses consider their AI initiatives fully mature, indicating massive room for growth and innovation.
Organizations aiming for long-term competitive advantage should consider centralized leadership oversight and proactive workflow redesign, ensuring AI implementations create lasting positive impacts on patient outcomes and operational efficiency.
AI’s role in healthcare is clear: It’s an essential, transformative force.
Businesses that are ready to adapt to these innovations can significantly enhance patient care, operational efficiencies, and medical outcomes.
The question now is not whether AI will shape the future of healthcare, but how swiftly and effectively businesses can integrate these technologies to lead in this new era of medicine.
If your business is thinking about how AI can transform your capabilities and accelerate your intelligence: then reach out today!
